98 related articles for article (PubMed ID: 22393833)
1. Antibacterial activity of clarithromycin loaded PLGA nanoparticles.
Valizadeh H; Mohammadi G; Ehyaei R; Milani M; Azhdarzadeh M; Zakeri-Milani P; Lotfipour F
Pharmazie; 2012 Jan; 67(1):63-8. PubMed ID: 22393833
[TBL] [Abstract][Full Text] [Related]
2. Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system.
Mohammadi G; Nokhodchi A; Barzegar-Jalali M; Lotfipour F; Adibkia K; Ehyaei N; Valizadeh H
Colloids Surf B Biointerfaces; 2011 Nov; 88(1):39-44. PubMed ID: 21752610
[TBL] [Abstract][Full Text] [Related]
3. Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori.
Lotfipour F; Valizadeh H; Milani M; Bahrami N; Ghotaslou R
Drug Res (Stuttg); 2016 Jan; 66(1):41-5. PubMed ID: 25919643
[TBL] [Abstract][Full Text] [Related]
4. Preparation and antibacterial activity of compound chitosan-compound Yizhihao-nanoparticles.
Ou S; Zhang YD
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 May; 33(5):369-74. PubMed ID: 18544838
[TBL] [Abstract][Full Text] [Related]
5. Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity.
Jeong YI; Na HS; Seo DH; Kim DG; Lee HC; Jang MK; Na SK; Roh SH; Kim SI; Nah JW
Int J Pharm; 2008 Mar; 352(1-2):317-23. PubMed ID: 18160236
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of antibacterial activity of caffeic acid phenethyl ester and PLGA nanoparticle formulation by different methods.
Arasoglu T; Derman S; Mansuroglu B
Nanotechnology; 2016 Jan; 27(2):025103. PubMed ID: 26629915
[TBL] [Abstract][Full Text] [Related]
7. Lectin-Conjugated Clarithromycin and Acetohydroxamic Acid-Loaded PLGA Nanoparticles: a Novel Approach for Effective Treatment of H. pylori.
Jain SK; Haider T; Kumar A; Jain A
AAPS PharmSciTech; 2016 Oct; 17(5):1131-40. PubMed ID: 26566630
[TBL] [Abstract][Full Text] [Related]
8. Anti-bacterial performance of azithromycin nanoparticles as colloidal drug delivery system against different gram-negative and gram-positive bacteria.
Azhdarzadeh M; Lotfipour F; Zakeri-Milani P; Mohammadi G; Valizadeh H
Adv Pharm Bull; 2012; 2(1):17-24. PubMed ID: 24312766
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives.
Liang JH; Wang YY; Wang H; Li XL; An K; Xu YC; Yao GW
Bioorg Med Chem Lett; 2010 May; 20(9):2880-3. PubMed ID: 20356738
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery.
Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G
J Drug Target; 2011 Jul; 19(6):409-17. PubMed ID: 20678034
[TBL] [Abstract][Full Text] [Related]
11. Development of azithromycin-PLGA nanoparticles: physicochemical characterization and antibacterial effect against Salmonella typhi.
Mohammadi G; Valizadeh H; Barzegar-Jalali M; Lotfipour F; Adibkia K; Milani M; Azhdarzadeh M; Kiafar F; Nokhodchi A
Colloids Surf B Biointerfaces; 2010 Oct; 80(1):34-9. PubMed ID: 20558048
[TBL] [Abstract][Full Text] [Related]
12. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles.
Esmaeili F; Hosseini-Nasr M; Rad-Malekshahi M; Samadi N; Atyabi F; Dinarvand R
Nanomedicine; 2007 Jun; 3(2):161-7. PubMed ID: 17468055
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli.
Shahverdi AR; Fakhimi A; Shahverdi HR; Minaian S
Nanomedicine; 2007 Jun; 3(2):168-71. PubMed ID: 17468052
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of erythromycin and clarithromycin against clinical isolates of Escherichia coli, Staphylococcus aureus, Klebsiella and Proteus by disc diffusion method.
Khan NW; Hassan F; Naqvi BS; Hasan SM
Pak J Pharm Sci; 2011 Jan; 24(1):25-9. PubMed ID: 21190914
[TBL] [Abstract][Full Text] [Related]
16. Activity of a novel series of acylides active against community-acquired respiratory pathogens.
Pandya M; Chakrabarti A; Rathy S; Katoch R; Venkataraman R; Bhateja P; Mathur T; Kumar GR; Malhotra S; Rao M; Bhadauria T; Barman TK; Das B; Upadhyay D; Bhatnagar PK
Int J Antimicrob Agents; 2010 Aug; 36(2):169-74. PubMed ID: 20493666
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains.
Ma S; Jiao B; Ju Y; Zheng M; Ma R; Liu L; Zhang L; Shen X; Ma C; Meng Y; Wang H; Qi Y; Ma X; Cui W
Eur J Med Chem; 2011 Feb; 46(2):556-66. PubMed ID: 21159410
[TBL] [Abstract][Full Text] [Related]
18. Bacterial effects and protein corona evaluations: crucial ignored factors in the prediction of bio-efficacy of various forms of silver nanoparticles.
Ashkarran AA; Ghavami M; Aghaverdi H; Stroeve P; Mahmoudi M
Chem Res Toxicol; 2012 Jun; 25(6):1231-42. PubMed ID: 22551528
[TBL] [Abstract][Full Text] [Related]
19. Ultrafine PEG-coated poly(lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications.
Chu CH; Wang YC; Huang HY; Wu LC; Yang CS
Nanotechnology; 2011 May; 22(18):185601. PubMed ID: 21415469
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
Nord CE; Lindmark A; Persson I
J Chemother; 1989 Jul; 1(4 Suppl):203-4. PubMed ID: 16312369
[No Abstract] [Full Text] [Related]
[Next] [New Search]
